The efficacy of pramipexole in the treatment of Parkinson's disease

Reviews in Contemporary Pharmacotherapy

Volumn 12, Issue 1-2, 2001, Pages 59-86

  Lieberman, A ^a   Minagar, A ^a   Pinter, M M ^a  

^a Box 15 ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR; LEVODOPA; PRAMIPEXOLE;

AREA UNDER THE CURVE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DYSKINESIA; HALLUCINATION; HUMAN; META ANALYSIS; MOTOR ACTIVITY; PARKINSON DISEASE; REVIEW; TREMOR;

EID: 0034965002     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Single-dose response to pramipexole in patients with Parkinson's disease
2. Prescription pricing guide. Indianapolis
3. Les catécholamines dans la maladie de parkinsonism
4. Long-term safety and efficacy of pramipexole in Parkinson's disease
5. Pramipexole - A novel dopamine agonist for the treatment of both early and late Parkinson's disease
6. Mechanisms of action of pramipexole: Putative neuroprotective effects
7. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole
8. Long-term safety and efficacy of pramipexole in early Parkinson's disease
9. Long-term safety and efficacy of pramipexole in early Parkinson's disease
10. Dopamine dependent reaction time deficits in patients with Parkinson's disease are task specific
11. Bromocriptine in Parkinson's disease
12. A three and a half year experience with pramipexole (PMPX) monotherapy in patients with early Parkinson's disease
13. Reduction of circulating 3-O-methyldopa by inhibition of catecholamine-O-methyltransferase with OR-611 and OR-462 in Cynomolgous monkeys: Implications for the treatment of Parkinson's disease
14. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
15. Aromatic amino acids and modification of parkinsonism
16. Mechanisms of action of pramipexole: Effects on receptors
17. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyraminalen systems
18. EuroQol - A new facility for the measurement of health related quality of life
19. Early combination therapy with bromocriptine and levodopa in Parkinson's disease
20. Parkinson's disease: An open label trial of pergolide in patients failing bromocriptine therapy
21. Adverse effects of levodopa in Parkinson's disease
22. Adverse effects of levodopa
23. Unified Parkinson's Disease Rating Scale
24. Unified Parkinson's Disease Rating Scale
25. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician
26. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease
27. Early combination of bromocriptine and levodopa in Parkinson's disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage
28. Chronic agonist therapy for Parkinson's disease: A five-year study of bromocriptine and pergolide
29. Agonist substitution in advanced Parkinson's disease
30. Switching dopamine agonists in advanced Parkinson's disease: Is rapid titration preferable to slow?
31. Lisuride pharmacology and treatment of Parkinson's disease
32. New pharmacotherapy for Parkinson's disease
33. Assessment of the effects of a D2-specific dopamine agonist (pramipexole) on motor behavior of Parkinson's disease (PD) patients
34. Bromocriptine: Problems with low-dose de novo therapy in Parkinson's disease
35. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
36. Abnormal involuntary movement scale
37. Ropinirole and pramipexole, the new agonists
38. The result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease
39. Parkinsonism: Onset, progression, and mortality
40. Cost effectiveness of pramipexole in Parkinson's disease in the US
41. Pramipexole versus levodopa in early Parkinson's disease: A randomized clinical trial
42. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia
43. Which risk factors predict the levodopa response in fluctuating Parkinson's disease?
44. Pramipexole in patients with early Parkinson's disease
45. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
46. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations
47. Long-term use of dopamine agonists in Parkinson's disease
48. The functional status questionnaire: Reliability and validity when used in primary care
49. Continuous and intermittent levodopa differentially affect basal ganglia function
50. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study
51. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease
52. Ropinirole: A dopamine agonist for the treatment of Parkinson's disease
53. Comparison of lisuride and bromocriptine in the treament of advanced Parkinson's disease
54. Assessment of Parkinson's disease
55. Clinical pharmacology of dopamine agonists in Parkinson's disease
56. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
57. New options for treatment of Parkinson's disease
58. Efficacy and safety of pramipexole in advanced PD patients with the 'wearing-off' phenomenon
59. Treatment of Parkinson's disease with bromocriptine
60. Pergolide in Parkinson's disease: Further studies
61. D-1 and D-2 agonists in Parkinson's disease
62. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
63. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats
64. The behavioural effects of pramipexole, a novel dopamine receptor agonist
65. Assessment of extrapyramidal disorders
66. Success and problems of long-term levodopa therapy in Parkinson's disease
67. Unified Parkinson's Disease Rating Scale characteristics and structure
68. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease
69. Treatment of Parkinson's disease should begin with a dopamine agonist
70. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms. Part II
71. L-dopa therapy of Parkinson's disease: Plasma L-dopa concentration, therapeutic response, and side effects
72. Pramipexole in the treatment of rest tremor in tremor-dominant or mixed-type Parkisnon's disease
73. Pramipexole in the treatment of tremor-dominant or mixed-type Parkinson's disease with predominant rest tremor
74. A multicenter double-blind placebo controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
75. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study
76. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study
77. Pramipexole vs levodopa as initial treatment for Parkinson's disease
78. Dopamine agonist dose escalation in healthy volunteers: Time course of tolerance development to pramipexole effects
79. Efficacy, safety and tolerance of the nonergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study
80. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: Prado study discontinued
81. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the Prado study
82. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease
83. Drug treatment of Parkinson's disease
84. A novel quantitative method for 3D measurement of Parkinsonian tremor
85. Disposition of ropinirole in animals and man
86. Long-term treatment of Parkinson's disease with bromocriptine
87. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination
88. Problems associated with long-term levodopa treatment of Parkinson's disease
89. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow up
90. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
91. Early dopamine agonist therapy in Parkinson's disease
92. Bromocriptine and the clinical spectrum of Parkinson's disease
93. A double blind comparative study of ropinirole versus bromocriptine in the treatment of parkinsonian patients not optimally controlled on L-dopa
94. Response fluctuations in Parkinson's disease
95. Dopamine autoreceptor agonists: Resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine
96. Projection technique for evaluating surgery in Parkinson's disease
97. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
98. Pramipexole vs levodopa in early Parkinson's disease: The randomized controlled CALM-PD trial
99. Evoked potentials, reaction time, and cognitive performance in on and off phases of Parkinson's disease
100. Bromocriptine: Long-term low-dose therapy in Parkinson's disease
101. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmstead County project
102. Rating impairment and disability in Parkinson's disease: Evaluation of the Unified Parkison's Disease Rating Scale
103. The initial treatment of Parkinson's disease should begin with levodopa
104. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease
105. Development and testing of the Parkinson's disease quality of life scale: The PDQUALIF
106. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease
107. The burden of Parkinson's disease on society, family, and the individual
108. The effect of a D2-specific dopamine agonist (pramipexole) on response time
109. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers
110. The population pharmacokinetics of pramipexole in Parkinson's disease patients
111. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen